07:00 , Apr 4, 2011 |  BioCentury  |  Strategy

Half-A-Loaf Dilemma

Cephalon Inc.'s board is evaluating the two options in last week's hostile takeover bid from Valeant Pharmaceuticals International Inc.: take the $5.7 billion in cash for the whole company, or take $2.8 billion for the...
07:00 , Mar 28, 2011 |  BioCentury  |  Product Development

Buying proof of concept

The potent antagonism of obatoclax against MCL1 and a look at undisclosed survival data from a Phase IIb trial drove Cephalon Inc.'s decision to buy Gemin X Pharmaceuticals Inc. last week for $225 million and...